Recipharm, a Swedish CDMO, announced a deal that will land the company its first facility in the U.S. with the purchase of Kemwell operations in America, Sweden and India.
The announcement Monday falls in the wake of Recipharm’s news last week that it is paying $102 million for a 72% stake in India’s Nitin Lifesciences.
The $205 million (SEK 1.7 billion) deal with Kemwell, which also is an India-based manufacturer, is structured in two parts. The first is for Recipharm to spend $85 million for Kemwell’s drug development business located in Research Triangle Park, NC, and other operations in Sweden. That’s supposed to close by the middle of this year.
The second part of the deal calls for Recipharm to spend $120 million for Kemwell’s India operations that include FDA-approved API manufacturing. It’s expected to close, pending Indian government approval, by the end of the year.
“These transactions represent a significant step in both the consolidation of the CDMO industry and the transformation of Recipharm into a global leader,” Thomas Eldered, Recipharm’s CEO, said in a statement. “We now have a U.S. footprint which we can use to further penetrate the world’s largest pharmaceutical market.”
Recipharm didn’t get Kemwell’s biopharma business as part of the deal, however, the Uppsala, Sweden-based company does have the right of first refusal if Kemwell decides to sell the unit.
By Joseph Keenan
Source: Fierce Pharma
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.